Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerenis: Aspiring to Esperion?

This article was originally published in Start Up

Executive Summary

When Esperion's ex-VP chemistry and technologies Jean-Louis Dasseux, PhD co-founded Cerenis Therapeutics in March 2005, he was doubtless inspired partly by Esperion's $1.25 billion sale to Pfizer in December 2003. So were a handful of top-notch VCs including Sofinnova Partners and HealthCap (a previous investor in Esperion), who poured in €25 million ($30.5 million) in August 2005.

You may also be interested in...



The A-List: 2005's Trend-Shaping Series A Financings

2005's top early stage venture financings reflect a drive for size and experience on the biotech side, and the demand for less-invasive procedures in the device world. Start-Up lists the top ten Series A rounds of 2005.

The A-List: 2005's Trend-Shaping Series A Financings

2005's top early stage venture financings reflect a drive for size and experience on the biotech side, and the demand for less-invasive procedures in the device world. Start-Up lists the top ten Series A rounds of 2005.

Positioning Acomplia: Has the Drug Arrived Before the Disease?

Sanofi-Aventis is the envy of many as it awaits approval for fat-busting metabolic syndrome drug, Acomplia. But obesity is rarely reimbursed; metabolic syndrome still undefined.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel